Portfolio

Director/PDMR Shareholding

By Sharecast

Date: Monday 22 Dec 2025






RNS Number : 4937M
GSK PLC
22 December 2025
 



GSK plc (the 'Company')


Transaction notification
































































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Wendy Becker



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



Ordinary shares of 31 ¼ pence each ('Ordinary Shares')


ISIN: GB00BN7SWP63



b)



Nature of the transaction



Purchase of 441 Ordinary Shares



c)



Price(s) and volume(s)






Price(s)



Volume(s)









£18.0909



441


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



London Stock Exchange (XLON)





 


























































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Elizabeth (Liz) McKee Anderson



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 201 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550


 



201


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)

































































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Charles Bancroft



b)



Position/status



Senior Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 1,577 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550



1,577


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)





   


























































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Dr Anne Beal



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 201 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550



201


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)





 


























































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Dr Hal Dietz



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 201 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550



201


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)

































































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Dr Jeannie Lee



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 202 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550



202


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)

































































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Dr Vishal Sikka



b)



Position/status



Independent Non-Executive Director



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



American Depositary Shares ('ADSs')


ISIN: US37733W2044



b)



Nature of the transaction



Purchase of 730 ADSs



c)



Price(s) and volume(s)






Price(s)



Volume(s)









$48.5550



730


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-19



f)



Place of the transaction


 



New York Stock Exchange (XNYS)

































































































1.



Details of PDMR/person closely associated with them ('PCA')



a)



Name



Lady Susan Symonds



b)



Position/status



PCA of Sir Jonathan Symonds (Non-Executive Chair)



c)



Initial notification/


amendment



Initial notification



2.



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



GSK plc



b)



LEI



5493000HZTVUYLO1D793



3.



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



a)



Description of the financial instrument



Ordinary shares of 31 ¼ pence each ('Ordinary Shares')


ISIN: GB00BN7SWP63



b)



Nature of the transaction



Purchase of 1,650 Ordinary Shares



c)



Price(s) and volume(s)






Price(s)



Volume(s)









£18.1046



1,650


















d)



Aggregated information


 


 



N/A (single transaction)



Aggregated volume Price






e)



Date of the transaction



2025-12-22



f)



Place of the transaction


 



London Stock Exchange (XLON)



 


About GSK


GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.


 


Registered in England & Wales:


No. 3888792


 


Registered Office:


79 New Oxford Street


London


WC1A 1DG






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFEDFFEEISEEE

« Go back to news channel

..

Email this article to a friend

or share it with one of these popular networks:


Top of Page